According to the current analysis of Reports and Data, the global Human Insulin market was valued at USD 24.88 Billion in 2018 and is expected to reach USD 46.59 Billion by year 2026, at a CAGR of 8.1%. The study covers insulin, an industrially manufactured replica of a peptide hormone produced by the pancreas for people whose bodies can't produce it on their own. Insulin is considered to be the primary anabolic hormone which is responsible for the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood promotes catabolism, which is the conversion of large molecules into smaller ones, especially of reserve body fat which may lead to numerous complications like loss of vision, unsteadiness of limbs, and obesity. A patient is prescribed different types of insulin based on many factors including their response to insulin and the patient's diet, alcohol intake and exercise to combat this lack of insulin.